
Opinion|Videos|July 29, 2024
Beyond EHA 2024: Promising Research in Multiple Myeloma to Watch
Author(s)Joseph Mikhael, MD
Dr. Mikhael discusses EHA 2024 data he found particularly noteworthy to share with colleagues.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- Please discuss any other data in multiple myeloma released at EHA 2024 that you find noteworthy to share with colleagues.
- Outside of EHA 2024 what ongoing research efforts are you most excited for in the treatment and management of multiple myeloma?
- What can we look forward to through the end of the year and beyond?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma
2
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
3
IEHP CEO Weighs in: Who Pays the Price When Millions Lose Medicaid Coverage?
4
Many US Health Care Workers Face Poverty, Food Insecurity, and Housing Instability
5
















































